biote Corp Dossier - Source-backed chat

biote Corp

BTMDNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.41

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.21Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $41M

Shares Outstanding 29.3M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Biote Corp. (BTMD) operates a highly specialized, capital-light practice-building platform in the high-growth hormone optimization space. While the company possesses a strong competitive moat through its proprietary Biote Method, clinical database, and high practitioner switching costs, near-term performance is heavily pressured by a voluntary recall of hormone pellets at its Asteria Health subsidiary. This recall has constrained supply, depressed gross margins, and temporarily slowed procedure volumes. Additionally, the recent sudden departure of CEO Bret Christensen in June 2026 introduces leadership transition risks. While management has maintained its full-year 2026 guidance (revenue above $190M and Adjusted EBITDA above $38M) and expects a recovery in the second half of the year, a 'Hold' recommendation is prudent until supply constraints are fully resolved and the new leadership team demonstrates stable execution.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$2.73

High · most bullish analyst$3.43

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Recall-related operational challenges and additional regulatory scrutiny from the FDA persist into the second half of 2026, causing prolonged supply disruptions. Practitioner attrition rates rise as clinics switch to alternative compounded hormone providers due to supply uncertainty. The leadership transition stalls, and elevated sales and technology investments fail to generate expected volume growth, leading to a guidance miss and further downward pressure on the stock.

Base CaseCentral scenario

The company successfully navigates the Asteria Health pellet recall, resolving supply constraints by the end of Q2 2026. The expanded sales force of 120 representatives successfully ramps up productivity, driving a recovery in procedure volumes in the second half of 2026. Dietary supplements continue their double-digit growth trajectory via e-commerce channels. Under Interim CEO Robert Peterson and Executive Chairman Marc Beer, the company achieves its FY 2026 guidance of revenue above $190 million and Adjusted EBITDA above $38 million, stabilizing the stock price.

Bull CaseUpside scenario

Successful vertical integration of Asteria Health expands gross margins by 200+ bps, while the resolution of the voluntary product recall drives a strong procedure volume recovery in H2 2026.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Capital-light business model with historically high gross margins (above 70%) and strong cash generation.
High practitioner retention and significant switching costs once the Biote Method is integrated into clinic workflows.
Robust growth in the high-margin dietary supplement segment, driven by successful e-commerce expansion.

Key Investment Risks

Regulatory and operational risks associated with the voluntary recall of compounded hormone pellets at Asteria Health.
Leadership transition uncertainty following the departure of CEO Bret Christensen in June 2026.
Concentration of revenue in compounded bioidentical hormone replacement therapy, which faces strict FDA oversight.

Thesis Invalidation Triggers

Failure to return to procedure revenue growth in the second half of 2026.
Further regulatory actions or warnings from the FDA regarding Asteria Health's manufacturing facility.
A material downward revision of the FY 2026 revenue guidance below $190 million.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.